DE69917750D1 - Oral verabreichbare galenische form mit rascher freisetzung und mit verzögerter freisetzung, enthaltend ein absorbtionspromoter und verwendung dieses absorbtionspromoters - Google Patents

Oral verabreichbare galenische form mit rascher freisetzung und mit verzögerter freisetzung, enthaltend ein absorbtionspromoter und verwendung dieses absorbtionspromoters

Info

Publication number
DE69917750D1
DE69917750D1 DE69917750T DE69917750T DE69917750D1 DE 69917750 D1 DE69917750 D1 DE 69917750D1 DE 69917750 T DE69917750 T DE 69917750T DE 69917750 T DE69917750 T DE 69917750T DE 69917750 D1 DE69917750 D1 DE 69917750D1
Authority
DE
Germany
Prior art keywords
promoter
absorbtion
absorbance
delayed release
rapidly released
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69917750T
Other languages
English (en)
Other versions
DE69917750T2 (de
Inventor
Olivier Saslawski
Philippe Giet
Dominique Michel
Thierry Hulot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of DE69917750D1 publication Critical patent/DE69917750D1/de
Application granted granted Critical
Publication of DE69917750T2 publication Critical patent/DE69917750T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69917750T 1998-02-23 1999-02-16 Oral verabreichbare galenische form mit rascher freisetzung und mit verzögerter freisetzung, enthaltend ein absorbtionspromoter und verwendung dieses absorbtionspromoters Expired - Lifetime DE69917750T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9802143A FR2775188B1 (fr) 1998-02-23 1998-02-23 Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
FR9802143 1998-02-23
PCT/EP1999/000994 WO1999042086A1 (en) 1998-02-23 1999-02-16 Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent

Publications (2)

Publication Number Publication Date
DE69917750D1 true DE69917750D1 (de) 2004-07-08
DE69917750T2 DE69917750T2 (de) 2005-05-25

Family

ID=9523244

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69917750T Expired - Lifetime DE69917750T2 (de) 1998-02-23 1999-02-16 Oral verabreichbare galenische form mit rascher freisetzung und mit verzögerter freisetzung, enthaltend ein absorbtionspromoter und verwendung dieses absorbtionspromoters
DE69939605T Expired - Lifetime DE69939605D1 (de) 1998-02-23 1999-02-16 Oral verabreichbare galenische Form enthaltend Metformin und einen Absorptionspromoter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69939605T Expired - Lifetime DE69939605D1 (de) 1998-02-23 1999-02-16 Oral verabreichbare galenische Form enthaltend Metformin und einen Absorptionspromoter

Country Status (28)

Country Link
US (2) US6426087B1 (de)
EP (2) EP1410791B1 (de)
JP (1) JP4828020B2 (de)
KR (1) KR100587181B1 (de)
CN (1) CN1182837C (de)
AP (1) AP2000001943A0 (de)
AR (2) AR018109A1 (de)
AT (2) ATE268164T1 (de)
AU (1) AU750785B2 (de)
BR (1) BR9908121A (de)
CA (1) CA2321267C (de)
CZ (1) CZ299366B6 (de)
DE (2) DE69917750T2 (de)
DK (2) DK1056445T3 (de)
ES (2) ES2222695T3 (de)
FR (1) FR2775188B1 (de)
HK (1) HK1035142A1 (de)
HU (1) HU226732B1 (de)
ID (1) ID26022A (de)
NO (1) NO20004190L (de)
OA (1) OA11454A (de)
PL (2) PL201851B1 (de)
PT (2) PT1056445E (de)
RU (1) RU2228201C2 (de)
SI (2) SI1410791T1 (de)
SK (2) SK285188B6 (de)
WO (1) WO1999042086A1 (de)
ZA (1) ZA991408B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
DE10026699A1 (de) 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
JP4459629B2 (ja) 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
FR2845289B1 (fr) * 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
EP1565583A4 (de) 2002-10-07 2007-11-21 Novartis Vaccines & Diagnostic Hiv-vakzine-formulierungen
US20040151769A1 (en) * 2002-12-31 2004-08-05 Boehringer Ingelheim International Gmbh Film coated tablet containing an extract of red vine leaves
ITRM20030074A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Formulazioni semisolide a rilascio immediato intese
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
NZ551340A (en) * 2004-04-22 2010-10-29 Boehringer Ingelheim Int Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder
WO2005123134A2 (en) * 2004-05-14 2005-12-29 Cadila Healthcare Limited A controlled release delivery system for metformin
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
BRPI0516869B1 (pt) * 2004-10-01 2018-01-30 Firmenich S.A. Microcápsula para perfumar ou aromatizar, métodos para a preparação de microcápsulas para perfumar ou aromatizar e para a redução da violência da explosão de uma composição em pó, uso de um supressor de explosão, e, produto perfumado, alimento, bebida ou produto farmacêutico
JP2008538741A (ja) * 2005-03-04 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 鬱病の治療用及び／又は予防用の医薬組成物
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
PE20061245A1 (es) * 2005-03-30 2007-01-06 Generex Pharm Inc Composiciones para la transmision transmucosa oral de la metformina
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
WO2006125042A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
CN101198328B (zh) * 2005-06-21 2011-04-06 默克专利股份有限公司 含有（r）-（-）-2-[5-（4-氟苯基）-3-吡啶基甲基氨基甲基]苯并二氢吡喃的固体药物制剂
EP1745788A1 (de) * 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007106957A1 (en) * 2006-03-21 2007-09-27 Laboratoires Smb S.A. Multiple units controlled-release floating dosage forms
ES2551093T3 (es) * 2006-05-09 2015-11-16 Sprout Pharmaceuticals, Inc. Uso de flibanserina para el tratamiento de trastornos del deseo sexual después de la menopausia
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
WO2008006838A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
JP5793828B2 (ja) * 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
EP2056797A2 (de) * 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH System mit kontrollierter freisetzung und verfahren zu seiner herstellung
US20080081142A1 (en) * 2006-10-03 2008-04-03 Zeik Douglas B Articles and methods for applying color on surfaces
EP1952803A1 (de) * 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Feste pharmazeutische Darreichungsform mit hydrierten Phospholipiden
US20090082464A1 (en) * 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090069419A1 (en) * 2007-09-07 2009-03-12 Bernd Jandeleit Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2042165A1 (de) * 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Hot-Melt-Befüllte Weichkapseln
TW200932734A (en) * 2007-10-15 2009-08-01 Xenoport Inc Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
US8226967B2 (en) 2008-11-27 2012-07-24 Basf Se Surface active proteins as excipients in solid pharmaceutical formulations
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2512455B8 (de) 2009-12-18 2014-07-23 FrieslandCampina Nederland Holding B.V. Co-verarbeitete tablettenunterstützungszusammensetzung sowie ihre herstellung und verwendung
JP5546900B2 (ja) * 2010-02-25 2014-07-09 ライオン株式会社 パナキサトリオール安定化組成物
US9000046B2 (en) 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
MX2014006574A (es) * 2011-12-02 2015-02-10 Synchroneuron Inc Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
KR102121404B1 (ko) * 2013-03-15 2020-06-11 썬 파마 글로벌 에프제트이 아비라테론 아세테이트 제제
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
JP2016520653A (ja) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
KR20200005576A (ko) * 2017-05-17 2020-01-15 컨플루언스 파마슈티컬스, 엘엘씨 호모타우린 및 이의 염의 제형
CN117835971A (zh) 2021-08-25 2024-04-05 巴斯夫欧洲公司 直接压片用辅料组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI63335B (fi) * 1979-02-02 1983-02-28 Orion Yhtymae Oy Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne
FR2457281A1 (fr) * 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
JPS62265226A (ja) * 1986-05-12 1987-11-18 Fujisawa Pharmaceut Co Ltd 経口投与用製剤
ZA898331B (en) * 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5139786A (en) * 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations
JPH03275633A (ja) * 1990-03-23 1991-12-06 Teikoku Seiyaku Co Ltd 生理活性ポリペプチドの吸収促進剤
US5138786A (en) 1991-07-17 1992-08-18 Fischer Michael G Insta-guard firearm protection
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon

Also Published As

Publication number Publication date
CN1182837C (zh) 2005-01-05
FR2775188B1 (fr) 2001-03-09
PL342162A1 (en) 2001-05-21
HUP0100970A2 (hu) 2001-08-28
NO20004190L (no) 2000-10-20
DE69939605D1 (de) 2008-10-30
JP2002503686A (ja) 2002-02-05
BR9908121A (pt) 2000-10-24
SK12552000A3 (sk) 2001-02-12
CA2321267C (en) 2007-04-17
ID26022A (id) 2000-11-16
AP2000001943A0 (en) 2000-12-31
EP1056445B1 (de) 2004-06-02
ATE408399T1 (de) 2008-10-15
KR100587181B1 (ko) 2006-06-08
PL201851B1 (pl) 2009-05-29
WO1999042086A1 (en) 1999-08-26
DK1056445T3 (da) 2004-10-04
ZA991408B (en) 1999-08-23
CZ299366B6 (cs) 2008-07-02
WO1999042086A9 (en) 2000-08-31
AR066843A2 (es) 2009-09-16
ATE268164T1 (de) 2004-06-15
HU226732B1 (en) 2009-08-28
KR20010034537A (ko) 2001-04-25
OA11454A (en) 2003-12-08
ES2222695T3 (es) 2005-02-01
AU3140899A (en) 1999-09-06
DK1410791T3 (da) 2009-01-12
SK285188B6 (sk) 2006-08-03
US6514524B1 (en) 2003-02-04
HK1035142A1 (en) 2001-11-16
CZ20002940A3 (cs) 2000-11-15
RU2228201C2 (ru) 2004-05-10
ES2314302T3 (es) 2009-03-16
PT1410791E (pt) 2008-12-24
CN1291091A (zh) 2001-04-11
SI1410791T1 (sl) 2009-02-28
AR018109A1 (es) 2001-10-31
DE69917750T2 (de) 2005-05-25
US6426087B1 (en) 2002-07-30
CA2321267A1 (en) 1999-08-26
NO20004190D0 (no) 2000-08-22
SI1056445T1 (en) 2004-10-31
JP4828020B2 (ja) 2011-11-30
HUP0100970A3 (en) 2001-12-28
EP1410791B1 (de) 2008-09-17
FR2775188A1 (fr) 1999-08-27
EP1056445A1 (de) 2000-12-06
SK286248B6 (sk) 2008-06-06
PL191415B1 (pl) 2006-05-31
EP1410791A1 (de) 2004-04-21
PT1056445E (pt) 2004-10-29
AU750785B2 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
DE69917750D1 (de) Oral verabreichbare galenische form mit rascher freisetzung und mit verzögerter freisetzung, enthaltend ein absorbtionspromoter und verwendung dieses absorbtionspromoters
NO20012139L (no) Multipartikkelformig sammensetning med modifisert frigjöring
ID28787A (id) 2-fenilbenzimidazol tersubstitusi, pembuatannya dan penggunaannya
ATE332294T1 (de) Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
EE200100185A (et) Asendatud fenüülderivaadid, nende valmistamine jakasutamine
AU6306398A (en) Single and double chain antibodies to the egf receptor, derivatives thereof and their use
EE04277B1 (et) Taksoidide klassi kuuluvate derivaatide valmistamismeetod
DE60004899D1 (de) SiC-C/C Verbundwerkstoff und seine Verwendungen
DE69728840D1 (de) Kojibiose Phosphorylase, deren Herstellung und Verwendung
ATE255569T1 (de) Indeno-, naphtho- und benzocyclohepta- dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel
DE69915066D1 (de) Biozide zusammensetzung und deren verwendung
DE69928140D1 (de) Antipicornavirale Verbindungen, deren Herstellung und Verwendung
DE60001307T2 (de) Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung
DE69940656D1 (de) Wegwerfwindel mit mechanischen Befestigungsmitteln
NO995591D0 (no) Geler med forsinket, langvarig frigjörelse
DK1070093T3 (da) Inhærent lys- og varmestabiliserede polyamider med forbedret vådægthed
DE69835433D1 (de) Disulfid-vernetzte glycoprotein-hormone, ihre herstellung und verwendung
DE69907802D1 (de) Thermisch wirkende Pflaster und seiner Verwendung
ATE261959T1 (de) Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
DE50002417D1 (de) 3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung
EE200100347A (et) 3,3-biarüülpiperidiini ja 2,2-biarüülmorfoliini derivaadid
DE69806419T2 (de) Harzzusammensetzung und ihre Verwendung
ATE212346T1 (de) 3-substituierte tetrahydropyridopyrimidinon- derivate, ihre herstellung und verwendung
DE69937090D1 (de) Halbleiterträger, seine Herstellung, Aufbau und dessen Herstellung
DE60005514D1 (de) Dormanz-brechende zusammenstezung und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition